What should I expect during FOLFIRI treatment for Colorectal Cancer

What to Expect During FOLFIRI Treatment for Colorectal Cancer

FOLFIRI is a combination chemotherapy regimen commonly used to treat colorectal cancer. Let me walk you through what this treatment involves, what happens during infusions, and what side effects you might experience.

What FOLFIRI Is

FOLFIRI is a shorthand name for four chemotherapy drugs given together:

• FOL = Leucovorin (a vitamin that helps 5-FU work better)
• F = Fluorouracil (5-FU), a chemotherapy drug
• IRI = Irinotecan, another chemotherapy drug
• OX = Oxaliplatin (a platinum-based drug)

According to the NCCN Guidelines for Colon Cancer, FOLFIRI is recommended as a first-line treatment option for patients with metastatic (advanced) colorectal cancer, often combined with targeted therapies like bevacizumab or anti-EGFR drugs depending on your tumor's genetic characteristics.

The Treatment Schedule

FOLFIRI is typically given in 2-week cycles. Here's what a typical cycle looks like:

Day 1 (Infusion Day):

• Leucovorin infusion over 2 hours
• Irinotecan infusion over 30-90 minutes
• 5-FU bolus (quick injection)
• 5-FU continuous infusion over 46-48 hours (you may go home with a portable pump)

Days 2-14:

• Recovery period while the continuous 5-FU infusion completes
• You'll have about 12 days before the next cycle begins

This cycle repeats until your doctor determines it's time to stop or switch treatments.

Common Side Effects to Expect

According to the NCCN Guidelines, irinotecan-based therapy is associated with several side effects that vary in severity:

Early Side Effects (During or shortly after treatment):

• Nausea and vomiting - Usually manageable with anti-nausea medications
• Diarrhea - Can be early (within hours) or late (days 3-5 after treatment). This is one of the more challenging side effects
• Fatigue - Very common; many patients feel tired for several days after treatment
• Loss of appetite
• Mouth sores
• Changes in taste

Blood Count Changes:

• Low white blood cells (increased infection risk)
• Low red blood cells (anemia, causing fatigue)
• Low platelets (increased bleeding/bruising risk)

Your doctor will monitor these with regular blood tests.

Longer-term Side Effects:

• Neuropathy (numbness and tingling in hands and feet) - This can develop over time with oxaliplatin exposure
• Hand-foot syndrome (tenderness, dryness, peeling of palms and soles)
• Cumulative toxicity - Some side effects worsen with repeated cycles

Important Genetic Consideration: UGT1A1 Testing

Here's something important: The NCCN Guidelines specifically note that irinotecan is broken down in your body by an enzyme called UGT1A1. Some people have genetic variations that affect how efficiently they process this drug.

What this means: If you have certain UGT1A1 genetic patterns (particularly the *28/*28 genotype), you may need a lower starting dose of irinotecan to reduce toxicity risk. A commercial test is available to check your UGT1A1 status.

Questions to ask your doctor:

• Should I have UGT1A1 testing before starting FOLFIRI?
• Do I have Gilbert syndrome or elevated bilirubin levels? (These also affect irinotecan tolerance)
• If so, will my dose be adjusted?

Managing Side Effects

The good news: Most side effects can be managed or prevented. According to treatment guidelines:

• Anti-nausea medications can be given preventatively before treatment
• Anti-diarrhea medications (like loperamide) can help manage diarrhea
• Nutritional support helps maintain strength
• Dose adjustments can be made if you experience severe toxicity
• Treatment breaks can be taken if needed

Important: Keep a daily log of side effects. If you experience severe diarrhea on days 3-5 of one cycle, your doctor can prescribe preventative anti-nausea medication for day 2 of your next cycle.

Oxaliplatin Discontinuation

According to the NCCN Guidelines, oxaliplatin should be strongly considered for discontinuation after 3-4 months of therapy (or sooner if you develop unacceptable nerve damage), while continuing the other agents. This helps prevent cumulative neuropathy while maintaining treatment benefit.

What Questions Should You Ask Your Oncologist?

1. Before starting: Do I need UGT1A1 genetic testing? Do I have any conditions that would affect irinotecan tolerance?

2. About your specific regimen: Will I receive FOLFIRI alone, or combined with bevacizumab or anti-EGFR therapy? Why?

3. About side effect management: What anti-nausea and anti-diarrhea medications will you prescribe preventatively?

4. About monitoring: How often will I have blood tests? What symptoms should prompt me to call immediately?

5. About duration: How long do you plan to treat with FOLFIRI? When will we reassess?

6. About oxaliplatin: When will we consider stopping oxaliplatin to reduce neuropathy risk?

Key Takeaway

FOLFIRI is an effective treatment for colorectal cancer, but it requires careful management of side effects. The good news is that oncologists have many tools to help you tolerate treatment better—from preventative medications to dose adjustments to treatment modifications. Open communication with your care team about how you're feeling is essential.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources cited:

• NCCN Guidelines for Colon Cancer (Version 5.2025) - Systemic Therapy for Advanced/Metastatic Disease
• American Cancer Society recommendations for colorectal cancer treatment